-DOCSTART- -X- -X- O

BRCA1 NN NN O
is NN NN O
secreted NN NN O
and NN NN O
exhibits NN NN O
properties NN NN O
of NN NN O
a NN NN O
granin NN NN O
. NN NN O

Ovarian NN NN B-Modifier
cancer NN NN I-Modifier
risk NN NN O
in NN NN O
BRCA1 NN NN O
carriers NN NN O
is NN NN O
modified NN NN O
by NN NN O
the NN NN O
HRAS1 NN NN O
variable NN NN O
number NN NN O
of NN NN O
tandem NN NN O
repeat NN NN O
( NN NN O
VNTR NN NN O
) NN NN O
locus NN NN O
. NN NN O

A NN NN O
novel NN NN O
homeodomain-encoding NN NN O
gene NN NN O
is NN NN O
associated NN NN O
with NN NN O
a NN NN O
large NN NN O
CpG NN NN O
island NN NN O
interrupted NN NN O
by NN NN O
the NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
unstable NN NN O
( NN NN O
CTG)n NN NN O
repeat NN NN O
. NN NN O

Germline NN NN O
mutations NN NN O
in NN NN O
the NN NN O
RB1 NN NN O
gene NN NN O
in NN NN O
patients NN NN O
with NN NN O
hereditary NN NN B-SpecificDisease
retinoblastoma NN NN I-SpecificDisease
. NN NN O

Type NN NN B-SpecificDisease
II NN NN I-SpecificDisease
human NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
C2 NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

Allele-specific NN NN O
amino NN NN O
acid NN NN O
substitutions NN NN O
( NN NN O
Ser189 NN NN O
-- NN NN O
> NN NN O
Phe NN NN O
; NN NN O

Gly444 NN NN O
-- NN NN O
> NN NN O
Arg NN NN O
) NN NN O
cause NN NN O
impaired NN NN O
C2 NN NN O
secretion NN NN O
. NN NN O

Defective NN NN O
dimerization NN NN O
of NN NN O
von NN NN B-Modifier
Willebrand NN NN I-Modifier
factor NN NN O
subunits NN NN O
due NN NN O
to NN NN O
a NN NN O
Cys-> NN NN O
Arg NN NN O
mutation NN NN O
in NN NN O
type NN NN B-SpecificDisease
IID NN NN I-SpecificDisease
von NN NN I-SpecificDisease
Willebrand NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

Wiskott-Aldrich NN NN B-Modifier
syndrome NN NN I-Modifier
protein NN NN O
, NN NN O
a NN NN O
novel NN NN O
effector NN NN O
for NN NN O
the NN NN O
GTPase NN NN O
CDC42Hs NN NN O
, NN NN O
is NN NN O
implicated NN NN O
in NN NN O
actin NN NN O
polymerization NN NN O
. NN NN O

X-linked NN NN B-SpecificDisease
adrenoleukodystrophy NN NN I-SpecificDisease
is NN NN O
a NN NN O
frequent NN NN O
cause NN NN O
of NN NN O
idiopathic NN NN O
Addison's NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
in NN NN O
young NN NN O
adult NN NN O
male NN NN O
patients NN NN O
. NN NN O

Tumor NN NN B-Modifier
suppression NN NN O
and NN NN O
apoptosis NN NN O
of NN NN O
human NN NN O
prostate NN NN B-SpecificDisease
carcinoma NN NN I-SpecificDisease
mediated NN NN O
by NN NN O
a NN NN O
genetic NN NN O
locus NN NN O
within NN NN O
human NN NN O
chromosome NN NN O
10pter-q11 NN NN O
. NN NN O

Low NN NN O
incidence NN NN O
of NN NN O
BRCA2 NN NN O
mutations NN NN O
in NN NN O
breast NN NN B-SpecificDisease
carcinoma NN NN I-SpecificDisease
and NN NN O
other NN NN O
cancers NN NN B-DiseaseClass
. NN NN O

Founding NN NN O
BRCA1 NN NN O
mutations NN NN O
in NN NN O
hereditary NN NN B-CompositeMention
breast NN NN I-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
in NN NN O
southern NN NN O
Sweden NN NN O
. NN NN O

Rapid NN NN O
detection NN NN O
of NN NN O
regionally NN NN O
clustered NN NN O
germ-line NN NN O
BRCA1 NN NN O
mutations NN NN O
by NN NN O
multiplex NN NN O
heteroduplex NN NN O
analysis NN NN O
. NN NN O

UKCCCR NN NN O
Familial NN NN O
Ovarian NN NN B-Modifier
Cancer NN NN I-Modifier
Study NN NN O
Group NN NN O
. NN NN O

A NN NN O
previously NN NN O
undescribed NN NN O
mutation NN NN O
within NN NN O
the NN NN O
tetramerisation NN NN O
domain NN NN O
of NN NN O
TP53 NN NN O
in NN NN O
a NN NN O
family NN NN O
with NN NN O
Li-Fraumeni NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

The NN NN O
spectrum NN NN O
of NN NN O
RB1 NN NN O
germ-line NN NN O
mutations NN NN O
in NN NN O
hereditary NN NN B-SpecificDisease
retinoblastoma NN NN I-SpecificDisease
. NN NN O

Phenotypic NN NN O
characterization NN NN O
of NN NN O
individuals NN NN O
with NN NN O
30-40 NN NN O
CAG NN NN O
repeats NN NN O
in NN NN O
the NN NN O
Huntington NN NN B-Modifier
disease NN NN I-Modifier
( NN NN O
HD NN NN B-Modifier
) NN NN O
gene NN NN O
reveals NN NN O
HD NN NN B-Modifier
cases NN NN O
with NN NN O
36 NN NN O
repeats NN NN O
and NN NN O
apparently NN NN O
normal NN NN O
elderly NN NN O
individuals NN NN O
with NN NN O
36-39 NN NN O
repeats NN NN O
. NN NN O

Identification NN NN O
and NN NN O
expression NN NN O
of NN NN O
eight NN NN O
novel NN NN O
mutations NN NN O
among NN NN O
non-Jewish NN NN O
patients NN NN O
with NN NN O
Canavan NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

Identification NN NN O
and NN NN O
chromosomal NN NN O
localization NN NN O
of NN NN O
Atm NN NN O
, NN NN O
the NN NN O
mouse NN NN O
homolog NN NN O
of NN NN O
the NN NN O
ataxia-telangiectasia NN NN B-Modifier
gene NN NN O
. NN NN O

The NN NN O
mouse NN NN O
homolog NN NN O
of NN NN O
the NN NN O
Wiskott-Aldrich NN NN B-Modifier
syndrome NN NN I-Modifier
protein NN NN O
( NN NN O
WASP NN NN O
) NN NN O
gene NN NN O
is NN NN O
highly NN NN O
conserved NN NN O
and NN NN O
maps NN NN O
near NN NN O
the NN NN O
scurfy NN NN O

( NN NN O
sf NN NN O
) NN NN O
mutation NN NN O
on NN NN O
the NN NN O
X NN NN O
chromosome NN NN O
. NN NN O

Colchicine NN NN O
in NN NN O
breast NN NN O
milk NN NN O
of NN NN O
patients NN NN O
with NN NN O
familial NN NN B-SpecificDisease
Mediterranean NN NN I-SpecificDisease
fever NN NN I-SpecificDisease
. NN NN O

Abnormal NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
protein NN NN O
kinase NN NN O
levels NN NN O
produce NN NN O
only NN NN O
mild NN NN O
myopathy NN NN B-DiseaseClass
in NN NN O
mice NN NN O
. NN NN O

Mice NN NN O
lacking NN NN O
the NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
protein NN NN O
kinase NN NN O
develop NN NN O
a NN NN O
late NN NN O
onset NN NN O
progressive NN NN O
myopathy NN NN B-SpecificDisease
. NN NN O

The NN NN O
tumor NN NN B-Modifier
suppressor NN NN O
gene NN NN O
Brca1 NN NN O
is NN NN O
required NN NN O
for NN NN O
embryonic NN NN O
cellular NN NN O
proliferation NN NN O
in NN NN O
the NN NN O
mouse NN NN O
. NN NN O

Increased NN NN O
coronary NN NN B-SpecificDisease
heart NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
in NN NN O
Japanese-American NN NN O
men NN NN O
with NN NN O
mutation NN NN O
in NN NN O
the NN NN O
cholesteryl NN NN O
ester NN NN O
transfer NN NN O
protein NN NN O
gene NN NN O
despite NN NN O
increased NN NN O
HDL NN NN O
levels NN NN O
. NN NN O

Mapping NN NN O
the NN NN O
homolog NN NN O
of NN NN O
the NN NN O
human NN NN O
Rb1 NN NN O
gene NN NN O
to NN NN O
chromosome NN NN O
14 NN NN O
of NN NN O
higher NN NN O
primates NN NN O
. NN NN O

Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
: NN NN O
no NN NN O
strict NN NN O
genotype-phenotype NN NN O
correlations NN NN O
but NN NN O
clustering NN NN O
of NN NN O
missense NN NN O
mutations NN NN O
in NN NN O
the NN NN O
amino-terminal NN NN O
part NN NN O
of NN NN O
the NN NN O
WASP NN NN O
gene NN NN O
product NN NN O
. NN NN O

Influence NN NN O
of NN NN O
PAX6 NN NN O
gene NN NN O
dosage NN NN O
on NN NN O
development NN NN O
: NN NN O
overexpression NN NN O
causes NN NN O
severe NN NN O
eye NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
. NN NN O

Heterodimer NN NN O
formation NN NN O
and NN NN O
activity NN NN O
in NN NN O
the NN NN O
human NN NN O
enzyme NN NN O
galactose-1-phosphate NN NN O
uridylyltransferase NN NN O
. NN NN O

Cleavage NN NN O
of NN NN O
huntingtin NN NN O
by NN NN O
apopain NN NN O
, NN NN O
a NN NN O
proapoptotic NN NN O
cysteine NN NN O
protease NN NN O
, NN NN O
is NN NN O
modulated NN NN O
by NN NN O
the NN NN O
polyglutamine NN NN O
tract NN NN O
. NN NN O

The NN NN O
5 NN NN O
' NN NN O
end NN NN O
of NN NN O
the NN NN O
BRCA1 NN NN O
gene NN NN O
lies NN NN O
within NN NN O
a NN NN O
duplicated NN NN O
region NN NN O
of NN NN O
human NN NN O
chromosome NN NN O
17q21 NN NN O
. NN NN O

Deletion NN NN O
of NN NN O
small NN NN O
nuclear NN NN O
ribonucleoprotein NN NN O
polypeptide NN NN O
N NN NN O
( NN NN O
SNRPN NN NN O
) NN NN O
in NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
detected NN NN O
by NN NN O
fluorescence NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
: NN NN O
two NN NN O
sibs NN NN O
with NN NN O
the NN NN O
typical NN NN O
phenotype NN NN O
without NN NN O
a NN NN O
cytogenetic NN NN O
deletion NN NN O
in NN NN O
chromosome NN NN O
15q NN NN O
. NN NN O

Expression NN NN O
of NN NN O
the NN NN O
von NN NN B-Modifier
Hippel-Lindau NN NN I-Modifier
disease NN NN I-Modifier
tumour NN NN I-Modifier
suppressor NN NN O
gene NN NN O
during NN NN O
human NN NN O
embryogenesis NN NN O
. NN NN O

Genetic NN NN O
heterogeneity NN NN O
in NN NN O
hereditary NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
: NN NN O
role NN NN O
of NN NN O
BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
. NN NN O

An NN NN O
intronic NN NN O
mutation NN NN O
in NN NN O
a NN NN O
lariat NN NN O
branchpoint NN NN O
sequence NN NN O
is NN NN O
a NN NN O
direct NN NN O
cause NN NN O
of NN NN O
an NN NN O
inherited NN NN B-DiseaseClass
human NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
( NN NN O
fish-eye NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
). NN NN O

Mutations NN NN O
associated NN NN O
with NN NN O
variant NN NN O
phenotypes NN NN O
in NN NN O
ataxia-telangiectasia NN NN B-SpecificDisease
. NN NN O

Mutation NN NN O
of NN NN O
the NN NN O
VHL NN NN O
gene NN NN O
is NN NN O
associated NN NN O
exclusively NN NN O
with NN NN O
the NN NN O
development NN NN O
of NN NN O
non-papillary NN NN B-SpecificDisease
renal NN NN I-SpecificDisease
cell NN NN I-SpecificDisease
carcinomas NN NN I-SpecificDisease
. NN NN O

The NN NN O
Emery-Dreifuss NN NN B-Modifier
muscular NN NN I-Modifier
dystrophy NN NN I-Modifier
protein NN NN O
, NN NN O
emerin NN NN O
, NN NN O
is NN NN O
a NN NN O
nuclear NN NN O
membrane NN NN O
protein NN NN O
. NN NN O

Mutation NN NN O
of NN NN O
MSH3 NN NN O
in NN NN O
endometrial NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
and NN NN O
evidence NN NN O
for NN NN O
its NN NN O
functional NN NN O
role NN NN O
in NN NN O
heteroduplex NN NN O
repair NN NN O
. NN NN O

Comparative NN NN O
genome NN NN O
mapping NN NN O
of NN NN O
the NN NN O
ataxia-telangiectasia NN NN B-Modifier
region NN NN O
in NN NN O
mouse NN NN O
, NN NN O
rat NN NN O
, NN NN O
and NN NN O
Syrian NN NN O
hamster NN NN O
. NN NN O

An NN NN O
animal NN NN O
model NN NN O
for NN NN O
Norrie NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
ND NN NN B-SpecificDisease
): NN NN O
gene NN NN O
targeting NN NN O
of NN NN O
the NN NN O
mouse NN NN O
ND NN NN B-Modifier
gene NN NN O
. NN NN O

The NN NN O
hybrid NN NN O
PAX3-FKHR NN NN O
fusion NN NN O
protein NN NN O
of NN NN O
alveolar NN NN B-SpecificDisease
rhabdomyosarcoma NN NN I-SpecificDisease
transforms NN NN O
fibroblasts NN NN O
in NN NN O
culture NN NN O
. NN NN O

Somatic-cell NN NN O
selection NN NN O
is NN NN O
a NN NN O
major NN NN O
determinant NN NN O
of NN NN O
the NN NN O
blood-cell NN NN O
phenotype NN NN O
in NN NN O
heterozygotes NN NN O
for NN NN O
glucose-6-phosphate NN NN O
dehydrogenase NN NN O
mutations NN NN O
causing NN NN O
severe NN NN O
enzyme NN NN B-DiseaseClass
deficiency NN NN I-DiseaseClass
. NN NN O

Analysis NN NN O
of NN NN O
meiotic NN NN O
segregation NN NN O
, NN NN O
using NN NN O
single-sperm NN NN O
typing NN NN O
: NN NN O
meiotic NN NN O
drive NN NN O
at NN NN O
the NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
locus NN NN O
. NN NN O

LPP NN NN O
, NN NN O
the NN NN O
preferred NN NN O
fusion NN NN O
partner NN NN O
gene NN NN O
of NN NN O
HMGIC NN NN O
in NN NN O
lipomas NN NN B-DiseaseClass
, NN NN O
is NN NN O
a NN NN O
novel NN NN O
member NN NN O
of NN NN O
the NN NN O
LIM NN NN O
protein NN NN O
gene NN NN O
family NN NN O
. NN NN O

Absence NN NN O
of NN NN O
disease NN NN O
phenotype NN NN O
and NN NN O
intergenerational NN NN O
stability NN NN O
of NN NN O
the NN NN O
CAG NN NN O
repeat NN NN O
in NN NN O
transgenic NN NN O
mice NN NN O
expressing NN NN O
the NN NN O
human NN NN O
Huntington NN NN B-Modifier
disease NN NN I-Modifier
transcript NN NN O
. NN NN O

FISH NN NN O
studies NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
sporadic NN NN B-SpecificDisease
aniridia NN NN I-SpecificDisease
and NN NN O
t(7 NN NN O
; NN NN O

11 NN NN O
) NN NN O
( NN NN O
q31.2 NN NN O
; NN NN O

p13 NN NN O
). NN NN O

Muscle NN NN O
expression NN NN O
of NN NN O
glucose-6-phosphate NN NN B-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
different NN NN O
variants NN NN O
. NN NN O

Gene NN NN O
therapy NN NN O
for NN NN O
phenylketonuria NN NN B-SpecificDisease
. NN NN O

Exon-intron NN NN O
structure NN NN O
of NN NN O
the NN NN O
human NN NN O
neuronal NN NN O
nicotinic NN NN O
acetylcholine NN NN O
receptor NN NN O
alpha NN NN O
4 NN NN O
subunit NN NN O
( NN NN O
CHRNA4 NN NN O
). NN NN O

Ashkenazi NN NN O
Jewish NN NN O
population NN NN O
frequencies NN NN O
for NN NN O
common NN NN O
mutations NN NN O
in NN NN O
BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
. NN NN O

Dual NN NN O
roles NN NN O
of NN NN O
ATM NN NN O
in NN NN O
the NN NN O
cellular NN NN O
response NN NN O
to NN NN O
radiation NN NN O
and NN NN O
in NN NN O
cell NN NN O
growth NN NN O
control NN NN O
. NN NN O

Targeted NN NN O
disruption NN NN O
of NN NN O
ATM NN NN O
leads NN NN O
to NN NN O
growth NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
, NN NN O
chromosomal NN NN B-SpecificDisease
fragmentation NN NN I-SpecificDisease
during NN NN I-SpecificDisease
meiosis NN NN I-SpecificDisease
, NN NN O
immune NN NN B-DiseaseClass
defects NN NN I-DiseaseClass
, NN NN O
and NN NN O
thymic NN NN B-SpecificDisease
lymphoma NN NN I-SpecificDisease
. NN NN O

Cloning NN NN O
and NN NN O
characterization NN NN O
of NN NN O
human NN NN O
very-long-chain NN NN O
acyl-CoA NN NN O
dehydrogenase NN NN O
cDNA NN NN O
, NN NN O
chromosomal NN NN O
assignment NN NN O
of NN NN O
the NN NN O
gene NN NN O
and NN NN O
identification NN NN O
in NN NN O
four NN NN O
patients NN NN O
of NN NN O
nine NN NN O
different NN NN O
mutations NN NN O
within NN NN O
the NN NN O
VLCAD NN NN O
gene NN NN O
. NN NN O

Molecular NN NN O
bases NN NN O
of NN NN O
combined NN NN B-SpecificDisease
subtotal NN NN I-SpecificDisease
deficiencies NN NN I-SpecificDisease
of NN NN I-SpecificDisease
C6 NN NN I-SpecificDisease
and NN NN I-SpecificDisease
C7 NN NN I-SpecificDisease
: NN NN O
their NN NN O
effects NN NN O
in NN NN O
combination NN NN O
with NN NN O
other NN NN O
C6 NN NN B-CompositeMention
and NN NN I-CompositeMention
C7 NN NN I-CompositeMention
deficiencies NN NN I-CompositeMention
. NN NN O

Genetic NN NN O
bases NN NN O
of NN NN O
human NN NN O
complement NN NN B-SpecificDisease
C7 NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

HPRT-APRT-deficient NN NN B-Modifier
mice NN NN O
are NN NN O
not NN NN O
a NN NN O
model NN NN O
for NN NN O
lesch-nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Somatic NN NN O
alterations NN NN O
of NN NN O
the NN NN O
DPC4 NN NN O
gene NN NN O
in NN NN O
human NN NN O
colorectal NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
in NN NN O
vivo NN NN O
. NN NN O

Pleiotropic NN NN O
defects NN NN O
in NN NN O
ataxia-telangiectasia NN NN B-Modifier
protein-deficient NN NN O
mice NN NN O
. NN NN O

The NN NN O
DCC NN NN O
protein NN NN O
and NN NN O
prognosis NN NN O
in NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Association NN NN O
of NN NN O
anxiety-related NN NN B-DiseaseClass
traits NN NN I-DiseaseClass
with NN NN O
a NN NN O
polymorphism NN NN O
in NN NN O
the NN NN O
serotonin NN NN O
transporter NN NN O
gene NN NN O
regulatory NN NN O
region NN NN O
. NN NN O

Phenotypic NN NN O
and NN NN O
genotypic NN NN O
overlap NN NN O
between NN NN O
atelosteogenesis NN NN B-SpecificDisease
type NN NN I-SpecificDisease
2 NN NN I-SpecificDisease
and NN NN O
diastrophic NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
. NN NN O

Identification NN NN O
of NN NN O
WASP NN NN O
mutations NN NN O
, NN NN O
mutation NN NN O
hotspots NN NN O
and NN NN O
genotype-phenotype NN NN O
disparities NN NN O
in NN NN O
24 NN NN O
patients NN NN O
with NN NN O
the NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Germline NN NN O
mutations NN NN O
in NN NN O
the NN NN O
3 NN NN O
' NN NN O
part NN NN O
of NN NN O
APC NN NN B-Modifier
exon NN NN O
15 NN NN O
do NN NN O
not NN NN O
result NN NN O
in NN NN O
truncated NN NN O
proteins NN NN O
and NN NN O
are NN NN O
associated NN NN O
with NN NN O
attenuated NN NN O
adenomatous NN NN B-SpecificDisease
polyposis NN NN I-SpecificDisease
coli NN NN I-SpecificDisease
. NN NN O

Complete NN NN O
genomic NN NN O
sequence NN NN O
and NN NN O
analysis NN NN O
of NN NN O
117 NN NN O
kb NN NN O
of NN NN O
human NN NN O
DNA NN NN O
containing NN NN O
the NN NN O
gene NN NN O
BRCA1 NN NN O
. NN NN O

Identification NN NN O
of NN NN O
a NN NN O
RING NN NN O
protein NN NN O
that NN NN O
can NN NN O
interact NN NN O
in NN NN O
vivo NN NN O
with NN NN O
the NN NN O
BRCA1 NN NN O
gene NN NN O
product NN NN O
. NN NN O

Detection NN NN O
of NN NN O
heterozygous NN NN O
mutations NN NN O
in NN NN O
BRCA1 NN NN O
using NN NN O
high NN NN O
density NN NN O
oligonucleotide NN NN O
arrays NN NN O
and NN NN O
two-colour NN NN O
fluorescence NN NN O
analysis NN NN O
. NN NN O

Autosomal NN NN B-SpecificDisease
dominant NN NN I-SpecificDisease
primary NN NN I-SpecificDisease
hyperparathyroidism NN NN I-SpecificDisease
and NN NN I-SpecificDisease
jaw NN NN I-SpecificDisease
tumor NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
associated NN NN O
with NN NN O
renal NN NN B-SpecificDisease
hamartomas NN NN I-SpecificDisease
and NN NN O
cystic NN NN B-DiseaseClass
kidney NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
: NN NN O
linkage NN NN O
to NN NN O
1q21-q32 NN NN O
and NN NN O
loss NN NN O
of NN NN O
the NN NN O
wild NN NN O
type NN NN O
allele NN NN O
in NN NN O
renal NN NN B-SpecificDisease
hamartomas NN NN I-SpecificDisease
. NN NN O

Independent NN NN O
origin NN NN O
of NN NN O
single NN NN O
and NN NN O
double NN NN O
mutations NN NN O
in NN NN O
the NN NN O
human NN NN O
glucose NN NN O
6-phosphate NN NN O
dehydrogenase NN NN O
gene NN NN O
. NN NN O

BRCA1 NN NN O
R841W NN NN O
: NN NN O
a NN NN O
strong NN NN O
candidate NN NN O
for NN NN O
a NN NN O
common NN NN O
mutation NN NN O
with NN NN O
moderate NN NN O
phenotype NN NN O
. NN NN O

Ataxia-telangiectasia NN NN B-SpecificDisease
: NN NN O
founder NN NN O
effect NN NN O
among NN NN O
north NN NN O
African NN NN O
Jews NN NN O
. NN NN O

Mutation NN NN O
analysis NN NN O
of NN NN O
BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
in NN NN O
a NN NN O
male NN NN B-Modifier
breast NN NN I-Modifier
cancer NN NN I-Modifier
population NN NN O
. NN NN O

Molecular NN NN O
basis NN NN O
for NN NN O
Duarte NN NN B-CompositeMention
and NN NN I-CompositeMention
Los NN NN I-CompositeMention
Angeles NN NN I-CompositeMention
variant NN NN I-CompositeMention
galactosemia NN NN I-CompositeMention
. NN NN O

The NN NN O
TSG101 NN NN O
tumor NN NN B-Modifier
susceptibility NN NN O
gene NN NN O
is NN NN O
located NN NN O
in NN NN O
chromosome NN NN O
11 NN NN O
band NN NN O
p15 NN NN O
and NN NN O
is NN NN O
mutated NN NN O
in NN NN O
human NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Moderate NN NN O
intergenerational NN NN O
and NN NN O
somatic NN NN O
instability NN NN O
of NN NN O
a NN NN O
55-CTG NN NN O
repeat NN NN O
in NN NN O
transgenic NN NN O
mice NN NN O
. NN NN O

Missense NN NN O
mutations NN NN O
in NN NN O
the NN NN O
Fas NN NN O
gene NN NN O
resulting NN NN O
in NN NN O
autoimmune NN NN B-SpecificDisease
lymphoproliferative NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
: NN NN O
a NN NN O
molecular NN NN O
and NN NN O
immunological NN NN O
analysis NN NN O
. NN NN O

The NN NN O
ataxia-telangiectasia NN NN B-Modifier
gene NN NN O
product NN NN O
, NN NN O
a NN NN O
constitutively NN NN O
expressed NN NN O
nuclear NN NN O
protein NN NN O
that NN NN O
is NN NN O
not NN NN O
up-regulated NN NN O
following NN NN O
genome NN NN O
damage NN NN O
. NN NN O

Type NN NN O
III NN NN O
collagen NN NN O
is NN NN O
crucial NN NN O
for NN NN O
collagen NN NN O
I NN NN O
fibrillogenesis NN NN O
and NN NN O
for NN NN O
normal NN NN O
cardiovascular NN NN O
development NN NN O
. NN NN O

Nonsense NN NN O
mutation NN NN O
in NN NN O
exon NN NN O
3 NN NN O
of NN NN O
the NN NN O
proteolipid NN NN O
protein NN NN O
gene NN NN O
( NN NN O
PLP NN NN O
) NN NN O
in NN NN O
a NN NN O
family NN NN O
with NN NN O
an NN NN O
unusual NN NN O
form NN NN O
of NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

Common NN NN O
BRCA1 NN NN O
variants NN NN O
and NN NN O
susceptibility NN NN O
to NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
in NN NN O
the NN NN O
general NN NN O
population NN NN O
. NN NN O

Kniest NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
: NN NN O
Dr NN NN O
. NN NN O
W NN NN O
. NN NN O
Kniest NN NN O
, NN NN O
his NN NN O
patient NN NN O
, NN NN O
the NN NN O
molecular NN NN O
defect NN NN O
. NN NN O

Cloning NN NN O
of NN NN O
the NN NN O
homogentisate NN NN O
1,2-dioxygenase NN NN O
gene NN NN O
, NN NN O
the NN NN O
key NN NN O
enzyme NN NN O
of NN NN O
alkaptonuria NN NN B-SpecificDisease
in NN NN O
mouse NN NN O
. NN NN O

PTEN NN NN O
, NN NN O
a NN NN O
putative NN NN O
protein NN NN O
tyrosine NN NN O
phosphatase NN NN O
gene NN NN O
mutated NN NN O
in NN NN O
human NN NN O
brain NN NN B-CompositeMention
, NN NN I-CompositeMention
breast NN NN I-CompositeMention
, NN NN I-CompositeMention
and NN NN I-CompositeMention
prostate NN NN I-CompositeMention
cancer NN NN I-CompositeMention
. NN NN O

Heterogeneity NN NN O
in NN NN O
Schwartz-Jampel NN NN B-SpecificDisease
chondrodystrophic NN NN I-SpecificDisease
myotonia NN NN I-SpecificDisease
. NN NN O

A NN NN O
clinical NN NN O
overview NN NN O
of NN NN O
WT1 NN NN O
gene NN NN O
mutations NN NN O
. NN NN O

A NN NN O
mutation NN NN O
in NN NN O
autosomal NN NN B-SpecificDisease
dominant NN NN I-SpecificDisease
myotonia NN NN I-SpecificDisease
congenita NN NN I-SpecificDisease
affects NN NN O
pore NN NN O
properties NN NN O
of NN NN O
the NN NN O
muscle NN NN O
chloride NN NN O
channel NN NN O
. NN NN O

The NN NN O
incidence NN NN O
of NN NN O
PAX6 NN NN O
mutation NN NN O
in NN NN O
patients NN NN O
with NN NN O
simple NN NN O
aniridia NN NN B-SpecificDisease
: NN NN O
an NN NN O
evaluation NN NN O
of NN NN O
mutation NN NN O
detection NN NN O
in NN NN O
12 NN NN O
cases NN NN O
. NN NN O

Insulin NN NN O
gene NN NN O
region NN NN O
contributes NN NN O
to NN NN O
genetic NN NN O
susceptibility NN NN O
to NN NN O
, NN NN O
but NN NN O
may NN NN O
not NN NN O
to NN NN O
low NN NN O
incidence NN NN O
of NN NN O
, NN NN O
insulin-dependent NN NN B-SpecificDisease
diabetes NN NN I-SpecificDisease
mellitus NN NN I-SpecificDisease
in NN NN O
Japanese NN NN O
. NN NN O

The NN NN O
human NN NN O
complement NN NN O
C9 NN NN O
gene NN NN O
: NN NN O
identification NN NN O
of NN NN O
two NN NN O
mutations NN NN O
causing NN NN O
deficiency NN NN O
and NN NN O
revision NN NN O
of NN NN O
the NN NN O
gene NN NN O
structure NN NN O
. NN NN O

BRCA1 NN NN O
mutations NN NN O
in NN NN O
women NN NN O
attending NN NN O
clinics NN NN O
that NN NN O
evaluate NN NN O
the NN NN O
risk NN NN O
of NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Mutations NN NN O
in NN NN O
the NN NN O
arginine-rich NN NN O
protein NN NN O
gene NN NN O
( NN NN O
ARP NN NN O
) NN NN O
in NN NN O
pancreatic NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Difficulties NN NN O
in NN NN O
the NN NN O
ascertainment NN NN O
of NN NN O
C9 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
: NN NN O
lessons NN NN O
to NN NN O
be NN NN O
drawn NN NN O
from NN NN O
a NN NN O
compound NN NN O
heterozygote NN NN O
C9-deficient NN NN B-Modifier
subject NN NN O
. NN NN O

Screening NN NN O
for NN NN O
ESR NN NN O
mutations NN NN O
in NN NN O
breast NN NN B-Modifier
and NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
patients NN NN O
. NN NN O

Molecular NN NN O
bases NN NN O
of NN NN O
C7 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
: NN NN O
three NN NN O
different NN NN O
defects NN NN O
. NN NN O

Molecular NN NN O
heterogeneity NN NN O
of NN NN O
classical NN NN B-CompositeMention
and NN NN I-CompositeMention
Duarte NN NN I-CompositeMention
galactosemia NN NN I-CompositeMention
: NN NN O
mutation NN NN O
analysis NN NN O
by NN NN O
denaturing NN NN O
gradient NN NN O
gel NN NN O
electrophoresis NN NN O
. NN NN O

Isolation NN NN O
of NN NN O
full-length NN NN O
ATM NN NN O
cDNA NN NN O
and NN NN O
correction NN NN O
of NN NN O
the NN NN O
ataxia-telangiectasia NN NN B-Modifier
cellular NN NN O
phenotype NN NN O
. NN NN O

Fusion NN NN O
genes NN NN O
resulting NN NN O
from NN NN O
alternative NN NN O
chromosomal NN NN O
translocations NN NN O
are NN NN O
overexpressed NN NN O
by NN NN O
gene-specific NN NN O
mechanisms NN NN O
in NN NN O
alveolar NN NN B-SpecificDisease
rhabdomyosarcoma NN NN I-SpecificDisease
. NN NN O

atm NN NN O
and NN NN O
p53 NN NN O
cooperate NN NN O
in NN NN O
apoptosis NN NN O
and NN NN O
suppression NN NN O
of NN NN O
tumorigenesis NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
resistance NN NN O
to NN NN O
acute NN NN B-SpecificDisease
radiation NN NN I-SpecificDisease
toxicity NN NN I-SpecificDisease
. NN NN O

Trinucleotide NN NN O
repeat NN NN O
expansion NN NN O
at NN NN O
the NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
locus NN NN O
reduces NN NN O
expression NN NN O
of NN NN O
DMAHP NN NN O
. NN NN O

Constitutively NN NN O
methylated NN NN O
CpG NN NN O
dinucleotides NN NN O
as NN NN O
mutation NN NN O
hot NN NN O
spots NN NN O
in NN NN O
the NN NN O
retinoblastoma NN NN B-Modifier
gene NN NN O
( NN NN O
RB1 NN NN O
). NN NN O

The NN NN O
von NN NN B-Modifier
Hippel-Lindau NN NN I-Modifier
tumor NN NN I-Modifier
suppressor NN NN O
gene NN NN O
product NN NN O
interacts NN NN O
with NN NN O
Sp1 NN NN O
to NN NN O
repress NN NN O
vascular NN NN O
endothelial NN NN O
growth NN NN O
factor NN NN O
promoter NN NN O
activity NN NN O
. NN NN O

Adult NN NN B-SpecificDisease
onset NN NN I-SpecificDisease
globoid NN NN I-SpecificDisease
cell NN NN I-SpecificDisease
leukodystrophy NN NN I-SpecificDisease
( NN NN O
Krabbe NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
): NN NN O
analysis NN NN O
of NN NN O
galactosylceramidase NN NN O
cDNA NN NN O
from NN NN O
four NN NN O
Japanese NN NN O
patients NN NN O
. NN NN O

